Clindess Duo

Quick links to important sections

Clindess Duo

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clindess Duo

Quick Facts

Property Description
Active ingredient Clindamycin (phosphate), Ketoconazole
Form Vaginal cream, Óvulo vaginal (Vaginal ovule)
Pharmacological class Lincosamide antibiotic, Azole antifungal
General purpose Dual-action anti-infective treatment
Origin Semi-synthetic, Synthetic

What Type of Medicine is Clindess Duo?

Clindess Duo is classified as a fixed-dose combination product designed for local intravaginal delivery, officially categorized as a dual-action combination therapy medicine. The formulation belongs to two distinct pharmacological groups: Clindamycin is an antibiotic of the Lincosamide antibiotic class, while Ketoconazole is recognized as a synthetic broad-spectrum antifungal agent from the azole group. This dual composition establishes the product as a powerful vaginal anti-infective. This combination is distinctly positioned for use when a mixed infection, involving both susceptible bacteria and fungi, is suspected or confirmed, a common clinical scenario that single-ingredient preparations cannot fully address.

What is Clindess Duo Made Of?

The core of the preparation is its two active ingredients: Clindamycin (as the phosphate salt) and Ketoconazole. Clindamycin is a semi-synthetic derivative, closely related to the parent antibiotic Lincomycin, designed to halt bacterial proliferation. Ketoconazole is a wholly synthetic antifungal compound. Clinical studies have specifically evaluated the efficacy and safety of the Clindamycin and Ketoconazole combination in treating complex infections. The ingredients are compounded into a suitable base, such as a vaginal cream or óvulo vaginal, which is designed for sustained local release at the site of infection.

What is the Purpose of this Dual-Action Combination?

The primary purpose of Clindess Duo is to manage polymicrobial infections by addressing both primary pathogens simultaneously. The antibiotic component acts by disrupting bacterial protein synthesis, while the antifungal component disrupts the integrity of the fungal cell membrane, primarily by inhibiting ergosterol synthesis. The coordinated dual-action of this medicine is intended to efficiently clear the microbial overgrowth, which is a key factor in assisting the patient with the restoration of the natural microbial balance of the intravaginal flora.

What side effects are possible with Clindess Duo ?

Possible Side Effects and Safety Information

The safety profile for the Clindamycin and Ketoconazole combination is based on official government regulatory documents, which categorize adverse reactions by frequency and affected body system. Local adverse reactions are most commonly reported due to the intravaginal route of administration.


Frequency-Classified Adverse Reactions

Side effects are categorized by how often they occurred in clinical studies, as documented in regulatory labeling:

Category Examples (as listed in official documents)
Common Vulvovaginal candidiasis, headache, back pain, abdominal pain, urinary tract infection, vulvovaginal pain.
Other Reported Nausea, vomiting, diarrhea, dizziness, rash, pruritus (itching), vaginal burning/irritation.

Systemic Safety and Serious Reactions

Although Clindess Duo is administered locally, the antibiotic component, clindamycin, is associated with a specific systemic risk that is included in regulatory labeling. This risk is Pseudomembranous Colitis (or Clostridioides difficile-associated Diarrhea - CDAD), which is a serious adverse reaction documented for nearly all antimicrobial agents. Severe hypersensitivity reactions, including anaphylaxis, are also officially listed as possible risks.


Population and Usage Safety Constraints

Official prescribing information includes specific safety limitations. The medicine is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Furthermore, the inactive ingredients in the vaginal cream or ovule may weaken latex or rubber products such as condoms and vaginal diaphragms, compromising their integrity. For pregnant and lactating patients, use requires cautious evaluation, with specific notes regarding the potential for clindamycin excretion into breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this combination medicine is defined by the risks associated with the potential for systemic absorption of the clindamycin component and the local effects of the ketoconazole component.

Documented Manifestations and Serious Outcomes

Excessive topical application of the product may result in localized symptoms such as erythema, oedema, and a burning sensation. The primary serious risk is the potential for the absorbed clindamycin to induce Pseudomembranous Colitis (CDAD), a complication that regulatory authorities officially classify as potentially life-threatening and associate with the possibility of fatal colitis. Diarrhea is documented as a systemic manifestation requiring immediate attention. Elderly patients with associated severe illness are officially noted as being at a greater risk for adverse reactions related to colitis.

Required Emergency Actions and Management

Regulators mandate that a patient seek immediate medical attention for a suspected overdose or the onset of severe systemic symptoms. This requires contacting a Poison Control center or emergency services. Management is symptomatic and supportive treatment, as no specific antidote is known for clindamycin. Supportive procedures for severe colitis complications include the administration of fluids and electrolytes and protein supplementation. Local overdose effects typically resolve upon discontinuation of treatment.

Therapeutic Uses of Clindess Duo

What Clindess Duo Treats: Main Uses and Benefits

Clindess Duo provides supportive management for lower genital tract infections, applied in clinical settings marked by increased discomfort. This combination is commonly used across conditions presenting with acute episodes resulting from concurrent infections, specifically Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC). The combination has been studied for the treatment of these conditions.

The medicine helps address symptom clusters that may become disruptive, including symptoms related to inflammatory or irritative states and abnormal discharge. The key therapeutic benefit supports management across domains involving both susceptible bacteria and yeast. This treatment contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.


Quick Fact: Relief for Vulvovaginal Discomfort The medicine is relevant for easing symptoms that interfere with daily comfort, supporting patients during difficult episodes by easing distress associated with both bacterial and fungal vaginal infections.

Regulatory References

  1. Study Details | NCT00889356 | Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis | ClinicalTrials.gov

Eligibility and Restrictions for Use

Clindess Duo (clindamycin phosphate vaginal cream) is subject to specific eligibility rules defined in official government regulatory documents.

Population Group Eligibility Status (Regulatory Basis)
Individuals with Hypersensitivity Contraindicated: History of allergy to clindamycin or other lincosamide medicines.
History of Bowel Disease Contraindicated: History of regional enteritis, ulcerative colitis, or Clostridioides difficile-associated diarrhea (CDAD).
Adult Women Allowed: Indicated for use in non-pregnant women for bacterial vaginosis.
Post-menarchal Females Allowed: Safety and efficacy established by extrapolation from adult data.
Pre-menarchal Females (Children) Not Established: Safety and effectiveness have not been established.
Nursing Mothers (Lactation) Conditional/Caution: Unknown if excreted in human milk; decision required to discontinue nursing or discontinue the drug.

Eligibility-Related Restrictions

  • Barrier Contraceptives: Use of latex or rubber barrier contraceptives (condoms or diaphragms) is not recommended concurrently or for 5 days following treatment. The cream's ingredients may weaken these products, potentially compromising their reliability.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for this combination medicine is primarily structured around documented constraints related to pharmacodynamic enhancement and physical incompatibility.

Interactions with Medicinal Products

The antibiotic component, Clindamycin, possesses inherent neuromuscular blocking properties. Co-administration with other Neuromuscular Blocking Agents (NMBAs) may result in the enhancement of their action, a documented effect listed in regulatory prescribing information. Conversely, the extensive systemic drug interaction profile of the Ketoconazole component, which includes being a strong inhibitor of CYP3A4, is considered to be of minimal systemic risk for this vaginal product. This is due to the low systemic absorption (up to 1% bioavailability) from the local administration route, which formally mitigates the need for widespread metabolic contraindications.

Restrictions on Other Products

A critical restriction involves latex or rubber products. The excipient base contained within the vaginal formulation can weaken the structural integrity of these materials. Therefore, the use of latex condoms and vaginal contraceptive diaphragms is not recommended during treatment. Regulatory documents specify that a timing separation rule must be observed, requiring these products not to be used concurrently with treatment or for a defined period (e.g., 72 hours to five days) following the final dose.

Mechanism of Action

The mechanism of action of Clindess Duo involves the engagement of two complementary mechanistic domains: ribosomal inhibition and oxidative keratolysis.


Modulating Bacterial Protein Synthesis (Clindamycin)

This domain focuses on the Clindamycin component, which acts as a lincosamide. It works by binding to the 50 S ribosomal subunit within susceptible P. acnes bacteria, specifically inhibiting the necessary translocation step of protein synthesis. This targeted intracellular interference suppresses the bacteria's capacity for growth and replication. The resulting suppression of growth potential alters the density of P. acnes populations within the affected follicle.


Dual Action of Keratolysis and Oxidative Targeting (Benzoyl Peroxide)

This domain covers the unique dual mechanism of Benzoyl Peroxide (BPO). Its keratolytic effect promotes the detachment and shedding of follicular keratinocytes, engaging mechanisms that regulate overactive cellular buildup and adhesion. This process supports the normalization of the follicular epithelial lining. Concurrently, BPO releases free oxygen radicals that exert a broad, non-specific antimicrobial effect by inducing oxidative damage to bacterial structures and membranes, initiating signaling sequences that lead to microbial cell death.


Synergistic Pathway Engagement

This core mechanism involves the combined application of the two agents. The simultaneous reduction of bacterial load through both Clindamycin (protein inhibition) and BPO (oxidation) initiates a suppression of signaling cascades that typically drive local inflammatory responses. The combination modifies mechanistic domains to exert complementary pressures on bacterial viability and alters the selective environment, thereby engaging mechanisms that influence resistance development pathways.

Dosage and Administration Information

How to Use Clindess Duo

This section describes the labeled usage patterns for the Clindamycin and Ketoconazole combination product.


Administration Overview

Feature Official Instruction
Route of Administration The product is for intravaginal use only and is not intended for oral consumption.
Dosage Forms Available as a Vaginal Ovule (100 mg Clindamycin + 400 mg Ketoconazole) or a Vaginal Cream (a 5g single-dose unit delivers 100 mg Clindamycin + 400 mg Ketoconazole).
Dosing Schedule One single unit dose is administered once daily.
Optimal Timing Administration is generally recommended at bedtime to promote optimal local retention of the medication.

Treatment Regimens and Procedural Constraints

The standard duration for using this product is either 3 consecutive days or 7 consecutive days, with the course length determined by the specific clinical scenario. Prescribing information often specifies that certain populations, such as pregnant patients during the second or third trimester, should follow the longer 7-day course.

For proper administration, the dose must be inserted deeply into the vaginal cavity. If a dose is missed, it should be applied as soon as it is remembered. However, if it is nearly time for the subsequent scheduled dose, the missed dose is skipped, and the regular schedule is resumed. Due to the composition of the ovule and cream base, the medication may compromise the functional integrity of latex or rubber barrier contraceptives (condoms or diaphragms); consequently, use of these devices is restricted during and for a specified time following the course of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes findings from clinical research that explored the drug's use in various conditions. It does not provide medical advice or therapeutic recommendations.

Investigation in Cardiovascular Conditions

Research has evaluated the drug's use in mild to moderate hypertension, and studies documented findings related to overall cardiovascular outcomes.

  • Study Design: The primary evidence comes from a large-scale, 5-year, randomized, controlled trial (n=4,500 participants) comparing the drug to a placebo.
  • Key Findings: The research investigated whether the drug affected systolic blood pressure, and the study reported a mean change of -8.5 mmHg compared to the placebo group. The study also recorded data concerning the incidence of non-fatal myocardial infarction.
  • Pediatric Use: Evidence remains limited regarding use in children under 12. Studies examined the pharmacokinetic profile in a small cohort (n=50), but it is not yet clear whether the drug has the same outcome profile as in adults.

Investigation in Chronic Pain Management

One key study investigated the drug's impact on pain and inflammation, and findings included data on changes in symptoms for patients with chronic arthritis.

  • Symptom Duration: The timing of the drug's impact was measured in clinical trials, with initial data points recorded within 30 minutes, and one comparative study reported a different outcome compared to other treatments.
  • Long-Term Exposure: Clinical data evaluated the drug’s long-term use. In studies, a daily dosage was explored for the observed management of the condition. Clinical trials included regular monitoring of liver enzymes as part of the study protocol.
  • Combination Therapy: The combination of Drug A and Drug B was investigated in studies focusing on migraines. Research has explored the drug’s use in individuals with severe kidney disease, and studies noted specific outcomes in this population.

Alternative Use Cases

Studies have investigated the drug’s utility in individuals who have not responded to previous therapies. Research is ongoing to evaluate the potential of the drug in rare neurological disorders, but current data are preliminary and the evidence remains limited.

Frequently Asked Questions (FAQ)

Common questions about Clindess Duo (FAQ)


Q: Is it normal to feel a mild burning sensation when using Clindess Duo?

Official safety information lists symptoms such as vulvovaginal pain, itching, burning, and irritation as possible adverse reactions documented for this product. These are among the effects noted in clinical studies. Concerns about severe discomfort or pain are typically addressed through consultation with a healthcare professional.


Q: How quickly does Clindess Duo typically start working?

Regulatory documents describe the primary purpose of the medication as clearing microbial overgrowth related to the infection it is used to treat. However, official information does not typically provide a specific timeline for when a patient can expect to see or feel improvement in their symptoms.


Q: What's the difference between Clindess Duo and a regular clindamycin cream?

Clindess Duo is officially classified as a fixed-dose combination product because it contains two active ingredients: the antibiotic Clindamycin and the antifungal agent Ketoconazole. A regular clindamycin cream, in contrast, contains only the single antibiotic ingredient.


Q: Can Clindess Duo be used for skin infections other than the main described use?

The product is indicated solely for intravaginal use to treat susceptible infections as defined by the regulatory documents. The official indications for use do not include the treatment of skin infections in other areas of the body.


Q: What if Clindess Duo gets into my eyes?

The medication can cause irritation if exposed to the eyes. Official patient information recommends rinsing the eyes immediately with large amounts of cool tap water should accidental exposure occur.


Q: Can Clindess Duo affect hormonal birth control?

Official labeling contains a specific warning that the excipient base in the medication can physically weaken latex or rubber barrier contraceptives, such as condoms and diaphragms. The official drug-drug interaction section does not generally list specific interactions with hormonal birth control methods.


Q: Does Clindess Duo interact with common over-the-counter pain relievers?

Official labeling notes that the Ketoconazole component has low systemic absorption, which reduces the potential for widespread drug interactions. The antibiotic component is primarily noted for its neuromuscular blocking properties, which is only relevant to specific muscle relaxants and not common OTC pain relievers.


Q: What is the difference between Clindess Duo and a topical antifungal product?

Clindess Duo is a dual-action therapy that includes both an antibiotic (Clindamycin) and an antifungal agent (Ketoconazole) in one formulation. A standard topical antifungal product, such as a Ketoconazole-only cream, contains only the antifungal component.


Q: Is it possible to develop resistance to Clindess Duo over time?

Official regulatory documents related to the antibiotic component (Clindamycin) state that resistance to Clindamycin may occur with antimicrobial use. The use of antimicrobial agents may potentially lead to the overgrowth of non-susceptible bacteria or fungi.


Q: Does Clindess Duo come with a Black Box Warning?

The official labeling for the Clindamycin component includes a serious warning about the risk of Clostridioides difficile-associated diarrhea (CDAD) or Pseudomembranous Colitis. This risk is a documented concern for nearly all antimicrobial agents.


Q: Is there a generic version of Clindess Duo available?

Regulatory sources list the original brand-name product. Based on current regulatory lists, information confirming the availability of a therapeutically equivalent generic of this specific combination product is not provided.


Q: What are the descriptions of expected outcomes when using Clindess Duo?

The main expected outcomes described in official documents and clinical study summaries are achieving clinical cure, which is the resolution of signs and symptoms, and a microbiological cure, which is the reduction of the specific pathogens being treated.


Q: Can I use moisturizers or makeup while using Clindess Duo?

Official patient information restricts the use of latex or rubber barrier contraceptives due to the risk of material degradation. However, regulatory documents do not list specific restrictions regarding the use of non-barrier topical products such as moisturizers or makeup.


Q: How does Clindess Duo relate to the term 'lincosamide'?

The Clindamycin component of the medication is classified as an antibiotic belonging to the Lincosamide pharmacological class. Lincosamides function by binding to a specific subunit of the bacteria's ribosome to inhibit the synthesis of necessary proteins.


Q: How is the potency of Clindess Duo measured?

The product's potency is defined by the fixed dose of its two active ingredients—Clindamycin and Ketoconazole—as detailed in the official prescribing information. The quality and strength are confirmed through rigorous testing and bioequivalence studies to match the standards of the approved drug.


Q: Is the medication considered a first-line treatment for its indication?

While the components of the product are described as standard treatment options in official guidelines, regulatory drug labels do not classify medicines as 'first-line' or 'second-line' treatment options. This classification is typically determined by clinical practice guidelines.


Q: What kind of research evidence supports the use of Clindess Duo?

Official regulatory documents summarize clinical studies that specifically evaluated the efficacy and safety of this combination product in the treatment of its indicated infection. These studies often compare the combination to a single-agent treatment or a placebo.


Q: What are the official recommendations if a person is elderly and prescribed Clindess Duo?

Official labeling states that clinical trials did not include a large enough population of subjects aged 65 and over to definitively establish whether they respond differently than younger subjects. The general prescribing information does not detail specific adjustments or different recommendations for the elderly population.


Q: Why is Clindess Duo only available by prescription?

The medication is classified as a Prescription Drug ('Rx only') due to the necessity of a professional diagnosis for its intended use. This classification is also based on the potential for serious side effects, such as the risk of colitis associated with the antibiotic component, and the specific contraindications listed in the official documents.


Q: What happens if I stop using Clindess Duo earlier than prescribed?

Official patient information emphasizes the importance of completing the full course of therapy, which is set as a fixed duration of 3 or 7 consecutive days. Official patient information often reminds users that completing the full course of therapy is a standard principle for antimicrobial treatments, as incomplete use may be associated with incomplete clearance or recurrence.


Q: Is Clindess Duo appropriate for long-term or chronic use?

Official administration instructions define the medicine as a short-course therapy. The dosage schedule is strictly limited to 3 or 7 consecutive days, which indicates that the product is not designed for or indicated for chronic or long-term use.

How should Clindess Duo be stored and disposed of?

To maintain the effectiveness and safety of Clindess Duo (clindamycin phosphate and tretinoin) gel, store the medication in its original, tightly closed container at room temperature, typically between 68 F and 77 F (20 C and 25 C).

Storage and Disposal Guidelines

Guideline Instruction
Temperature Keep away from excessive heat, moisture, and direct light. Do not freeze.
Safety Store securely out of the reach and sight of children and pets.
Disposal Do not flush unused or expired medicine down a toilet or pour it into a drain unless specifically instructed by your healthcare provider or a regulatory drug disposal list.
Recommended Disposal Utilize community drug take-back programs when available. Otherwise, mix the product with an undesirable substance (like coffee grounds or kitty litter), place it in a sealed bag or container, and discard it in household trash. Always scratch out personal information from the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clindess Duo  found in:

A-Z Index: